|
gptkbp:instanceOf
|
gptkb:drug
gptkb:triptan
|
|
gptkbp:approvalYear
|
2002
2002 (US)
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
N02CC06
|
|
gptkbp:brand
|
Relpax
|
|
gptkbp:CASNumber
|
143322-58-1
|
|
gptkbp:category
|
gptkb:serotonin_receptor_agonist
antimigraine agent
|
|
gptkbp:chemicalClass
|
gptkb:indole_derivative
|
|
gptkbp:contraindication
|
stroke
ischemic heart disease
uncontrolled hypertension
|
|
gptkbp:developer
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
4-5 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasMolecularFormula
|
C22H26N2O2S
|
|
gptkbp:KEGGID
|
D07913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
5-HT1B/1D receptor agonist
|
|
gptkbp:MedlinePlusID
|
a603018
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
85%
|
|
gptkbp:PubChem_CID
|
CHEMBL121
119369
DB00218
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
dry mouth
|
|
gptkbp:synonym
|
Eletriptan hydrobromide
|
|
gptkbp:UNII
|
8Y164V895Y
|
|
gptkbp:usedFor
|
migraine
|
|
gptkbp:bfsParent
|
gptkb:Triptans
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eletriptan
|